Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
FDA considered the planned HER-096 Phase 2a study design appropriateStudy design finalized; approximately 100 patients to be enrolledMore than 50% of Phase 2 funding secured or identified Espoo,...
-
FDA considered the planned HER-096 Phase 2a study design appropriateStudy design finalized; approximately 100 patients to be enrolledMore than 50% of Phase 2 funding secured or identified Espoo,...
-
Leveraging deep scientific and clinical expertise in MPNs to drive a pipeline of disease-modifying precision therapies that selectively target disease-driving cellsAdvancing AT-01, a first-in-class...
-
SAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Halo Biosciences, a clinical stage biopharmaceutical company today announced that its Chief Executive Officer, Anissa Kalinowski, MSc, MBA, will...
-
SAN DIEGO, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced completion of patient enrollment in the pivotal Phase 3 FORT Study, which is evaluating the safety and...